Argent BioPharma Limited (ASX:RGT)
Australia · Delayed Price · Currency is AUD 0.0360
0.00 (0.00%)
May 12, 2026, 1:19 PM AEST
Argent BioPharma Income Statement
Financials in millions AUD. Fiscal year is July - June.
Millions AUD. Fiscal year is Jul - Jun.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
| 0.35 | 0.18 | 0.89 | 3.39 | 4.73 | 3 | |
Revenue Growth (YoY) | 17.56% | -79.74% | -73.69% | -28.41% | 57.94% | 44.10% |
Cost of Revenue | 0.98 | 0.78 | 1.2 | 2.04 | 4.17 | 1.9 |
Gross Profit | -0.64 | -0.6 | -0.3 | 1.35 | 0.56 | 1.1 |
Selling, General & Admin | 6.97 | 12.12 | 15.56 | 13.34 | 11.83 | 7.79 |
Research & Development | 3.36 | 3.59 | 2.32 | 2.99 | - | - |
Other Operating Expenses | -1.12 | -0.67 | -0.16 | 0.22 | 4.23 | 5.25 |
Operating Expenses | 9.22 | 15.04 | 17.72 | 16.56 | 16.06 | 13.04 |
Operating Income | -9.86 | -15.64 | -18.02 | -15.21 | -15.5 | -11.94 |
Interest Expense | -0.05 | -0.05 | -0.48 | -0.26 | -0.21 | -0.37 |
Interest & Investment Income | 0 | 0 | 0 | 0 | 0 | 0.01 |
Currency Exchange Gain (Loss) | 0.36 | 0.36 | 0.83 | -1.22 | 0.08 | -0.03 |
Other Non Operating Income (Expenses) | 2.13 | - | 0.06 | 0.09 | -1.24 | -3.57 |
EBT Excluding Unusual Items | -7.42 | -15.33 | -17.61 | -16.6 | -16.86 | -15.9 |
Impairment of Goodwill | - | - | - | -3.15 | -3.9 | - |
Gain (Loss) on Sale of Investments | -0.03 | -1.41 | 1.34 | -1.39 | - | - |
Gain (Loss) on Sale of Assets | -0.18 | -0.12 | -0.02 | - | - | - |
Asset Writedown | -0.98 | -0.98 | -1.26 | - | - | - |
Pretax Income | -8.62 | -17.84 | -17.55 | -21.13 | -20.77 | -15.9 |
Income Tax Expense | - | - | - | 0 | - | -0.03 |
Earnings From Continuing Operations | -8.62 | -17.84 | -17.55 | -21.13 | -20.77 | -15.87 |
Net Income to Company | -8.62 | -17.84 | -17.55 | -21.13 | -20.77 | -15.87 |
Minority Interest in Earnings | - | - | 0.02 | 0.31 | 0.42 | 0 |
Net Income | -8.62 | -17.84 | -17.53 | -20.82 | -20.35 | -15.87 |
Net Income to Common | -8.62 | -17.84 | -17.53 | -20.82 | -20.35 | -15.87 |
Shares Outstanding (Basic) | 70 | 57 | 37 | 3 | 3 | 2 |
Shares Outstanding (Diluted) | 70 | 57 | 37 | 3 | 3 | 2 |
Shares Change (YoY) | 37.70% | 54.47% | 1155.86% | 14.85% | 34.63% | 37.91% |
EPS (Basic) | -0.12 | -0.31 | -0.47 | -7.07 | -7.93 | -8.33 |
EPS (Diluted) | -0.12 | -0.31 | -0.47 | -7.10 | -7.93 | -8.33 |
Free Cash Flow | -7.61 | -9.28 | -14.8 | -12.18 | -14.85 | -15.32 |
Free Cash Flow Per Share | -0.11 | -0.16 | -0.40 | -4.13 | -5.79 | -8.04 |
Gross Margin | -183.19% | - | -34.13% | 39.88% | 11.89% | 36.70% |
Operating Margin | -2834.03% | -8663.31% | -2022.52% | -448.91% | -327.54% | -398.48% |
Profit Margin | -2477.93% | -9882.48% | -1967.34% | -614.71% | -430.00% | -529.70% |
Free Cash Flow Margin | -2189.04% | -5140.45% | -1661.19% | -359.40% | -313.85% | -511.23% |
EBITDA | -9.82 | -15.08 | -16.95 | -14.67 | -15.4 | -11.6 |
D&A For EBITDA | 0.04 | 0.56 | 1.08 | 0.54 | 0.1 | 0.34 |
EBIT | -9.86 | -15.64 | -18.02 | -15.21 | -15.5 | -11.94 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.